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Total (dialysate plus residual renal) creatinine clearance deter-
mination is an accepted method of assessing adequacy of dialysis
in CAPD patients [1, 2]. However, there are at least three major
disadvantages to this approach. First, it is a time consuming,
laborious procedure requiring accurate collection and cumber-
some and tedious processing of urine, dialysate, and plasma. It is
heavily dependent on patient cooperation and nursing coordina-
tion. Second, nursing staff are frequently obligated to handle
bulky quantities of potentially infectious body fluids. Third,
because traditional CAPD adequacy measurements may be math-
ematically coupled to measurements of protein catabolic rate [3,
4], an independent measure of solute removal would be advanta-
geous. In this study we tested the hypothesis that plasma iohexol
clearance acts as a simple surrogate for the more intensive
methodologies now in use.
The use of single injections of exogenous markers to determine
GFR is of great inherent value [5]. lohexol is a low osmolality,
nonionic, iodinated radiologic contrast agent which has been in
clinical use in adults and children for over a decade. More recently
iohexol has demonstrated utility as a measure of glomerular
filtration rate in patients undergoing urography or angiography
[6—9]. Numerous studies validate the observed agreement in GFR
estimates derived from plasma iohexol clearance and those de-
rived from clearances of radiolabeled chelates or inulin [6, 7,
9—13]. Therefore, we have applied this proven methodology to
CAPD adequacy measurements.
Methods
The present study was approved by the Human Research
Advisory Committee (Institutional Review Board) at each partic-
ipating site. Informed consent was obtained from each patient
prior to the study. Thirty-seven patients with end-stage renal
disease maintained on continuous ambulatory peritoneal dialysis
were studied. All patients were clinically stable (especially in
weight) and without peritonitis at the time of the study. Their
normal dialysis prescription was maintained throughout the study.
Patients with a known sensitivity to contrast agents or with a
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stated allergy to iodine or shellfish were excluded from participa-
tion.
Traditional clearance studies
All urine and dialysate was collected for a 24 hour period.
Creatinine concentration was determined in plasma, urine and
dialysate by the modified Jaffe reaction [14]. Dialysate creatinine
concentration was corrected for dialysate glucose concentration.
The correction factor was determined by measuring the reported
creatinine concentration in fresh 2.5% glucose dialysate. Urea
concentration was determined by the enzymatic conductivity rate
method employing a Beckman conductivity electrode on a Beck-
man Synchron CX7® System (Beckman Instruments, Inc., Brea,
CA, USA). The presence of iohexol in the sample was determined
not to interfere (< 3% difference) with either of these assays.
Urinary and dialytic creatinine clearance for each patient was
calculated using the standard clearance formula. Total weekly
creatinine clearance (total Cr in Fig. 1) was determined by the
summation of the contributions of dialytic and urinary creatinine
clearance for 24 hours and multiplying by seven. This clearance is
expressed in liters/week/1.73 m2 to facilitate routine clinical use.
Another method of measuring adequacy of dialysis is by the
summation of dialytic creatinine clearance and GFR, with GFR
being defined as the mean of urinary urea and creatinine clear-
ance (denoted as Dialysate CCr + GFR in Fig. 2).
Plasma iohexol clearance methodology
Fifteen to twenty milliliters of iohexol (Omnipaque®-300,
Sanofi Winthrop, New York, NY, USA) were injected intrave-
nously over three to five minutes. After distribution (4 to 6 hr
post-injection), a plasma sample was obtained and the 24 hour
period for collection of urine and dialysate was begun. A second
plasma sample was taken 24 hours later. After separation, the
plasma sample was stored at 4°C until analysis. The samples were
allowed to reach room temperature and were then analyzed for
iodine concentration by X-ray fluorescence using a Renalyzer®
(Provalid AB, Lund, Sweden). Analysis (counting) time was 300
seconds per sample. The X-ray fluorescence technique of the
Renalyzer® has an accuracy of greater than 99% over the range
of concentrations measured in this study and an overall coefficient
of variation of approximately 2% [15]. The Renalyzer® under-
goes automatic recalibration every twenty minutes to minimize
errors resulting from changes in ambient conditions.
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Fig. 1. Relationship of total plasma iohexol clearance and total weekly
creatinine clearance. (y = 0.061x + 3.11; N = 37, r = 0.806, P < 0.001)
Plasma iohexol clearance was calculated automatically by the
Renalyzer® from these two samples using a one compartment
kinetic model with the correction of Brochner-Mortensen [16] as
follows. When concentration versus time plots are constructed for
a marker substance, the clearance is a function of the dose and the
area under the concentration-time curve (AUC). The formula for
one compartment clearance is given by:
CI = D/AUC or D X lcd/B (Eq. 1)
where Cl is clearance in mi/mm, D is dose administered (of
iodine) in mg, kei is the elimination rate constant in min1, and B
is the concentration at time 0 (intercept on the ordinate) in mg/mi.
The rate constant and the intercept are determined by the least
square method. The output from the Renalyzer® is in ml/min/
1.73 m2 of plasma iohexol clearance.
The mono-exponential model will overestimate the true clear-
ance due to an underestimate of the AUC caused by neglecting
the high plasma concentrations of the marker substance during
the distribution phase. The correction of Bröchner-Mortensen
applied to the clearance formula for the one compartment model
was determined empirically by correlating total plasma clearances
of 51Cr-EDTA obtained from data fitted to a three or four
exponential model with those fitted to a one compartment model
for determination of AUC. The relationship between the two
methodologies yielded the formula:
Cl = 0.990778 X Cl1 — 0.001218 X Cl1 (Eq. 2)
where Cl is the corrected clearance and Cl1 is the clearance
calculated using a one compartment model to determine area
under the concentration-time curve (AUC).
The correction factors applied to the one compartment kinetic
model have been derived in an attempt to account for some
factors (assumptions) which make the mathematically simplistic,
yet clinically useful one-compartment model more relevant to
actual clinical situations. They minimize the errors resulting from
AUC determination and allow for fewer plasma samples without
overly compromising the accuracy of the clearance calculation.
The robustness of this technique is evidenced by the further
simplification in sampling strategy (single sample method) math-
ematically derived from a one compartment model by Jacobsson
[17]. Corrections for non-immediate mixing and non-uniform
distribution are introduced. They have almost negligible impact
on the clearance calculation at low clearances. Even large devia-
tions from expected distribution volumes do not significantly alter
clearance values obtained when an appropriately long sampling
strategy is used. Our sampling strategy used a second sampling
time point approximately 28 to 30 hours after injection, which
would approach the optimal sampling time for subjects with
clearances in the range seen in dialysis patients. The good
agreement between the one point and multiple point method
substantiate the empiric corrections determined by Bröchner-
Mortensen and make their use applicable to the methodology
employed in our study.
Data analysis
Correlations between total plasma iohexoi clearance and both
traditional peritoneal dialysis adequacy methods were determined
by linear regression analysis with statistical significance set at a =
0.05.
Results
Figure 1 illustrates the highly correlated relationship (r =0.806,
P < 0.001) between total plasma iohexol clearance and total
weekly creatinine clearance. Plotting iohexol clearance against
dialysate creatinine clearance + GFR yields a similarly high
correlation (r = 0.795) for the regression line as shown in Figure
2.
Discussion
Many CAPD patients depend on residual renal function as a
major contributor to total clearance. Of paramount importance is
that iohexol not negatively affect residual renal function. The
toxicity profile of iohexol has been extensively evaluated and it is
considered to be the least nephrotoxic contrast agent currently
available [18]. There is a low incidence of nephrotoxicity when
iohexol has been used in high risk patient populations such as
diabetics [19], patients with renal disease [8, 20—22], and renal
transplant recipients [23].
Due to the higher cost of low osmolality nonionic agents,
controversy remains as to the superiority or preferability of
nonionic versus ionic, low osmolality versus high osmolality agents
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Fig. 2. Relationship of total plasma iohexol clearance and dialysate creati-
nine clearance + GFR (mean of urea and creatinine residual renal clear-
ance). (y = 0.67x + 2.69; N = 28, r = 0.795, P < 0.001).
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lack of an accepted definition of renal toxicity or a consensus of
what constitutes clinically important nephrotoxicity. For example,
agents differ in their propensity to induce urinary excretion of
various renal tubular enzymes; the choice of enzyme to monitor
will influence the observed pattern of toxicity for a particular
agent [24—271. When less sensitive indices of renal dysfunction
(such as serum creatinine, or albumin excretion) are used to
define nephrotoxicity, there may be no noticeable difference
between agents of differing types [28]. The most expansive
investigation into the safety of iohexol was a year long multicenter
prospective trial in which over 50,000 patients were evaluated for
subjective and objective findings in an effort to ascertain the
incidence of adverse events [29]. Over half the patients were
considered high risk. Overall, adverse reactions were noted in
2.1% of patients, with the high risk patients exhibiting a rate of
2.7%. Only six patients had severe (hospitalization requiring)
events and there were no fatalities associated with iohexol admin-
istration. Despite the preponderance of high risk patients, iohexol
was demonstrated to be better tolerated than conventional agents
by historical controls [29—31]. Frennby et a! [22] was not able to
demonstrate any change in nephrotoxicity parameters (creatinine,
albumin excretion, urinary tubular proteins) in 21 patients with
severe chronic renal impairment. In the only study that assessed
the effect of iohexol on residual renal function in dialysis patients,
St. Peter et al found no difference in residual renal function by
traditional urine collections after iohexol administration in a
group of hemodialysis patients [32, manuscript in preparation,
personal communication with Dr. Sue Swan].
lohexol plasma clearance offers several advantages over tradi-
tional CAPD adequacy testing. The plasma iohexol clearance
methodology is considerably less labor intensive, requiring only an
intravenous injection and two subsequent plasma samples, which
In conclusion, our data suggest plasma iohexol clearance may
be used as a simple and reliable marker of CAPD adequacy in lieu
of traditional methodologies.
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